Petition Argues FDA Has Overstepped In PGx Regulation
Executive Summary
A group of manufacturers and clinicians is asking the US agency to allow more discussion between manufacturers, labs and clinicians of how genetic factors could influence drug effectiveness – an area known as pharmacogenomics (PGx). The FDA had previously taken several steps to limit these communications.
You may also be interested in...
Top FDA Officials Warn About Non-Vetted Pharmacogenetic Tests After Latest 23andMe Approval
A day after 23andMe gained US FDA go-ahead for a DTC genetic test service to inform patients about their ability to metabolize medications, the agency issued a safety communication, paired with a joint statement from device- and drug-center heads, warning consumers against trusting genetic tests that have not been vetted by FDA.
Proposed Rule Would Apply FDA’s Diagnostic Rules To LDTs
A proposed rule from the US Food and Drug Administration would allow the agency to take on regulation of lab-developed tests by phasing out the previous approach of enforcement discretion
OMB Clears Proposed Rule On Lab-Developed Tests
The US FDA appears poised to release long-promised regulations on lab-developed tests. However, some industry observers still have doubts as to whether the agency is truly prepared.